Fourth Quarter and FY 2025 Earnings Conference Call © Copyright Adaptive Biotechnologies 2026. Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not cons ...

Financial Performance - MRD revenue reached $49.9 million, a 42% year-over-year increase[6] - Excluding milestones, MRD revenue grew by 38% year-over-year[6] - Total revenue increased by 36% to $58.9 million[31] - Sequencing gross margin increased to 64%, up 14 percentage points year-over-year[6] - The company's cash position is strong at $222 million[6] - Q2 2025 cash burn was approximately $11 million, a 36% decrease compared to Q2 2024[6] MRD Business - Clinical testing revenue increased by 57% year-over-year in Q2 2025[9] - clonoSEQ US volume reached 24,624 tests in Q2 2025[10] - 44% of MRD tests were conducted in blood in Q2 2025[11] - MRD pharma backlog is approximately $218 million, a 21% year-over-year growth[19]